ReviewPLoS neglected tropical diseases2014
Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.
Review in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05611710 (Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Use of pyriproxyfen in control of Aedes mosquitoes: A systematic review.PLoS neglected tropical diseases · 2020Pooled it
- Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Dengue Knowledge and Preventive Practices in Iquitos, Peru.The American journal of tropical medicine and hygiene · 2015Trial
- Dengue therapeutics consortium 2025: a global collaboration in action.BMJ public health · 2026Review
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.Military Medical Research · 2024Review
- Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial.Wellcome open research · 2024Article
- Article
- Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions.Molecules (Basel, Switzerland) · 2023Review
- Review of Importance of Weather and Environmental Variables in Agent-Based Arbovirus Models.International journal of environmental research and public health · 2022Review
- Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses.PLoS neglected tropical diseases · 2022Review
- Article
- A Review:Vaccines · 2021Review
- Article
- Natural and nature-inspired stilbenoids as antiviral agents.European journal of medicinal chemistry · 2020Review
- Metformin as adjunctive therapy for dengue in overweight and obese patients: a protocol for an open-label clinical trial (MeDO).Wellcome open research · 2020Article
- Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies.Infection and drug resistance · 2019Article
- Clinical prognostic models for severe dengue: a systematic review protocol.Wellcome open research · 2019Article
- Development of standard clinical endpoints for use in dengue interventional trials.PLoS neglected tropical diseases · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 6 countries.
Funding
Abstract
Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.